Skip to main content

Oncorus, Inc. (ONCR)

NASDAQ: ONCR · Delayed Price · USD
9.47 -0.10 (-1.04%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap261.68M
Revenue (ttm)n/a
Net Income (ttm)-62.37M
Shares Out25.65M
EPS (ttm)-3.46
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume52,900
Open9.50
Previous Close9.57
Day's Range9.35 - 9.76
52-Week Range9.01 - 37.86
Betan/a
AnalystsBuy
Price Target37.25 (+293.3%)
Est. Earnings DateNov 3, 2021

About ONCR

Oncorus, Inc., a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca ...

IndustryBiotechnology
IPO DateOct 2, 2020
Employees56
Stock ExchangeNASDAQ
Ticker SymbolONCR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for Oncorus stock is "Buy." The 12-month stock price forecast is 37.25, which is an increase of 293.35% from the latest price.

Price Target
$37.25
(293.35% upside)
Analyst Consensus: Buy

News

Oncorus Reports Second Quarter 2021 Financial Results and Provides Business Highlights

CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today reported ...

1 month ago - GlobeNewsWire

Oncorus Expands its Board with Appointment of Barbara Yanni

-- Former Merck executive brings extensive experience in corporate development, licensing and  financial evaluation, and expertise advising clinical stage public biopharmaceutical companies -- CAMBRIDGE...

1 month ago - GlobeNewsWire

Oncorus Appoints Eric Rubin, M.D. to its Board of Directors

-- Renowned academic and industry leader brings deep expertise in oncology translational research and drug development, including pioneering work at Merck on KEYTRUDA® (pembrolizumab) -- CAMBRIDGE, Mass...

3 months ago - GlobeNewsWire

Oncorus to Host Investor Day Featuring its IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Platform and Lead...

CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced...

3 months ago - GlobeNewsWire

Oncorus Announces Nomination of its First IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Product Candidates...

CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced ...

3 months ago - GlobeNewsWire

Oncorus to Present at Upcoming Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced ...

3 months ago - GlobeNewsWire

Oncorus Reports First Quarter 2021 Financial Results and Provides Business Highlights

-- Enrollment continues in Phase 1 clinical trial of lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate ONCR-177; initial interim data expected in 2H'21 -- -- Company plans to nomi...

4 months ago - GlobeNewsWire

The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.

7 months ago - Benzinga

7 of the Best Swing Trade Stocks Available Right Now

These are 7 of the best swing trade stocks on the market right now, but you need to have a strategy and rules in order to be safe. The post 7 of the Best Swing Trade Stocks Available Right Now appeared ...

Other symbols:GOOGLGSLMBPDULXLRE
7 months ago - InvestorPlace

Oncorus Secures $57M Via Equity At 9% Discount

Oncorus Inc (NASDAQ: ONCR) prices of its underwritten public offering of 3 million common shares at $19 per share, raising $57 million in gross proceeds. The offer price represents a discount of 9% on t...

7 months ago - Benzinga

Oncorus Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies to tran...

7 months ago - GlobeNewsWire

Oncorus Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies to tran...

7 months ago - GlobeNewsWire

Oncorus: Buy On A Dip, Potential Already Priced In At Current Levels

Oncorus Inc.'s share price has risen by over 120% in about three months of listing. ONCR's novel technology is still a reason to consider the stock as an investment in emerging biopharmaceutical, but th...

7 months ago - Seeking Alpha

Oncorus Announces Publication of Preclinical Data Demonstrating Potent Systemic Antitumor Activity of its Clinical St...

-- Preclinical findings show that ONCR-177's systemic antitumor immunity is driven by its  five complementary immunomodulatory transgene payloads and retention of γ 34.5 -- -- Complete and durable tumor...

8 months ago - GlobeNewsWire

Oncorus to Build GMP Viral Immunotherapy Clinical Manufacturing Facility in Andover, Mass.

-- 88,000 square foot state-of-the-art facility will support Oncorus' advancing, multi-product  pipeline of intratumorally and intravenously administered viral immunotherapies –

8 months ago - GlobeNewsWire

Oncorus to Participate in Fireside Chats at Upcoming Piper Sandler Annual Healthcare Conference and Evercore ISI Heal...

CAMBRIDGE, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announced today ...

10 months ago - GlobeNewsWire

Oncorus Reports Third Quarter 2020 Financial Results and Provides Business Highlights

-- Received $98.4 million in aggregate gross proceeds in October from initial public offering -- -- Initiated Phase 1 clinical trial of lead viral immunotherapy candidate, ONCR-177, for the treatment of...

10 months ago - GlobeNewsWire

Oncorus to Present at Chardan 4th Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outc...

11 months ago - GlobeNewsWire

Oncorus Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc., a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes for cancer...

11 months ago - GlobeNewsWire

Oncorus Finalizes $87 Million U.S. IPO Effort

Oncorus Finalizes $87 Million U.S. IPO Effort

11 months ago - Seeking Alpha

Biotech Oncorus to offer 5.8 million shares in planned IPO, priced at $14 to $16 each

Biotech Oncorus Inc. set terms for its initial public offering on Monday with plans to offer 5.8 million shares priced at $14 to $16 each.

11 months ago - Market Watch